BEDFORD, Mass., October 17, 2023 Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on October 16th, 2023, the company granted a stock option to purchase an aggregate of 32,800 shares of common stock to 1 new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases –BEDFORD, Mass. (BUSINESS WIRE) Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating prote.
– Data from multiple ongoing clinical studies of STK-001 show reductions in convulsive seizure frequency and improvements in cognition and behavior in children and adolescents with Dravet syndrome –– Data support the potential for STK-001 to be the first disease-modifying treatment for Dravet syndrome –– New pharmac.